ArticleInternational journal of endocrinology2026
Biochemical Predictors and Clinical Characteristics for the Development of Cytopenia and Bone Marrow Involvement Among Patients With Primary Hyperparathyroidism.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochemical Predictors and Clinical Characteristics for the Development of Cytopenia and Bone Marrow Involvement Among Patients With Primary Hyperparathyroidism.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical features associated with primary hyperparathyroidism (PHPT) giving rise to bone marrow fibrosis are poorly documented. We hypothesised that the severity of PHPT may contribute to the development of this complication. Methods: We identified two clinical cases managed within our clinical service and reviewed case reports and cohort studies using search terms, Results: We identified a total of 41 reports that satisfied our search criteria, comprising individual cases and three previously reported cohorts. Of these, 27 cases were excluded as they had secondary hyperparathyroidism from renal failure, or because an alternative aetiology for bone marrow fibrosis, such as toxin exposure, was identified. In addition, one large cohort of patients with PHPT and cytopenia was excluded due to the absence of a bone marrow biopsy and missing key biochemical and skeletal data. The included reports consisted of 11 individual cases of bone marrow fibrosis associated with PHPT, along with 2 small cohorts of 17 and 8 patients, respectively. Common clinical features across the 11 case reports included markedly elevated parathyroid hormone (PTH) levels (mean ± SD: 130 ± 95.8 pmol/L; normal range: 1.1-6.9 pmol/L), low serum 25-hydroxyvitamin D (median [IQR]: 20.0 [17.0-30.0] nmol/L; normal range: 75-150 nmol/L) and significantly elevated alkaline phosphatase (ALP) (median [IQR]: 361 [293-1372]) U/L; normal range: 30-120 U/L). Bone marrow fibrosis in this instance is reversible following excision of the culprit parathyroid lesion. Conclusion: Bone marrow fibrosis associated with PHPT occurs predominantly in the setting of severe biochemical disease, characterised by markedly elevated PTH and ALP levels and may present with variable patterns of cytopenia. While symptom duration varies widely, disease severity rather than chronicity appears to be the principal determinant for bone marrow involvement. Haematological abnormalities are reversible following parathyroidectomy, highlighting the importance of timely diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.